fleischhacker w w brooks d j (45 résultats)

4°, Original-Pappband. 141 Seiten. Illustriert. Exemplar noch originalverschweißt. Nahezu neuwertig. - in englischer Sprache. IS: 3211262911 ****An unsere Kunden in Deutschland: Versand nach Deutschland einmal in der Woche ab Freilassing mit der Deutschen Post.*** - Sprache: Englisch Gewicht in Gramm: 550.

Etat : New.

Paperback. Etat : new. Paperback. The 5th Neuropsychiatry Symposium of the European Institute of Health- care was devoted to neuropsychopharmacology. As in previous meetings, we sought to choose topics that bridge the gap between basic neuroscience and the clinical fields of neurology and psychiatry. Consequently, the pro- ceedings published in this supplement cover a lot of ground. Late breaking data on various neuromodulator and neurotransmitter systems and their implications for the treatment of a number of disorders are reviewed. Jean- Charles Schwartz and colleagues set the stage with their paper on constitu- tive receptor activity, using the histamine H3-receptor to illustrate the point. The role of neuropeptides and neurotrophins in psychiatric disorders is then reviewed by Florian Holsboer, while Bill Deakin elucidates the role of sero- tonin, discovered 50 years ago in the brain, in select psychiatric syndromes. New pharmacological developments in the treatment of migraine, Parkin- son's disease and schizophrenia are then presented by Hans Christoph Diener, Eduardo Tolosa and Wolfgang Fleischhacker.In the end David Nutt and colleagues provide future directions in substance dependence research, linking the role of various transmitter systems with findings from neu- roimaging studies. In summary, there is no doubt that progress in the field of neuropsychopharmacology is exciting and the prospects of true advances in the treatment of brain disorders are very promising. The 5th Neuropsychiatry Symposium of the European Institute of HealthA care was devoted to neuropsychopharmacology. As in previous meetings, we sought to choose topics that bridge the gap between basic neuroscience and the clinical fields of neurology and psychiatry. Consequently, the proA ceedings published in this supplement cover a lot of ground. Late breaking data on various neuromodulator and neurotransmitter systems and their implications for the treatment of a number of disorders are reviewed. JeanA Charles Schwartz and colleagues set the stage with their paper on constituA tive receptor activity, using the histamine H3-receptor to illustrate the point. The role of neuropeptides and neurotrophins in psychiatric disorders is then reviewed by Florian Holsboer, while Bill Deakin elucidates the role of seroA tonin, discovered 50 years ago in the brain, in select psychiatric syndromes. New pharmacological developments in the treatment of migraine, ParkinA son's disease and schizophrenia are then presented by Hans Christoph Diener, Eduardo Tolosa and Wolfgang Fleischhacker. In the end David Nutt and colleagues provide future directions in substance dependence research, linking the role of various transmitter systems with findings from neuA roimaging studies. In summary, there is no doubt that progress in the field of neuropsychopharmacology is exciting and the prospects of true advances in the treatment of brain disorders are very pro Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Etat : New.

Etat : As New. Unread book in perfect condition.

Etat : New. In.

Etat : New. pp. 117 1st Edition.

Etat : New.

Etat : New.

Etat : New.

Etat : New.

Buch. Etat : Neu. Neuware -The 5th Neuropsychiatry Symposium of the European Institute of Health care was devoted to neuropsychopharmacology. As in previous meetings, we sought to choose topics that bridge the gap between basic neuroscience and the clinical fields of neurology and psychiatry. Consequently, the pro ceedings published in this supplement cover a lot of ground. Late breaking data on various neuromodulator and neurotransmitter systems and their implications for the treatment of a number of disorders are reviewed. Jean Charles Schwartz and colleagues set the stage with their paper on constitu tive receptor activity, using the histamine H3-receptor to illustrate the point. The role of neuropeptides and neurotrophins in psychiatric disorders is then reviewed by Florian Holsboer, while Bill Deakin elucidates the role of sero tonin, discovered 50 years ago in the brain, in select psychiatric syndromes. New pharmacological developments in the treatment of migraine, Parkin son's disease and schizophrenia are then presented by Hans Christoph Diener, Eduardo Tolosa and Wolfgang Fleischhacker. In the end David Nutt and colleagues provide future directions in substance dependence research, linking the role of various transmitter systems with findings from neu roimaging studies. In summary, there is no doubt that progress in the field of neuropsychopharmacology is exciting and the prospects of true advances in the treatment of brain disorders are very promising.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 132 pp. Englisch.

Etat : New. In.

Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - The 5th Neuropsychiatry Symposium of the European Institute of Health care was devoted to neuropsychopharmacology. As in previous meetings, we sought to choose topics that bridge the gap between basic neuroscience and the clinical fields of neurology and psychiatry. Consequently, the pro ceedings published in this supplement cover a lot of ground. Late breaking data on various neuromodulator and neurotransmitter systems and their implications for the treatment of a number of disorders are reviewed. Jean Charles Schwartz and colleagues set the stage with their paper on constitu tive receptor activity, using the histamine H3-receptor to illustrate the point. The role of neuropeptides and neurotrophins in psychiatric disorders is then reviewed by Florian Holsboer, while Bill Deakin elucidates the role of sero tonin, discovered 50 years ago in the brain, in select psychiatric syndromes. New pharmacological developments in the treatment of migraine, Parkin son's disease and schizophrenia are then presented by Hans Christoph Diener, Eduardo Tolosa and Wolfgang Fleischhacker. In the end David Nutt and colleagues provide future directions in substance dependence research, linking the role of various transmitter systems with findings from neu roimaging studies. In summary, there is no doubt that progress in the field of neuropsychopharmacology is exciting and the prospects of true advances in the treatment of brain disorders are very promising.

Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - The 5th Neuropsychiatry Symposium of the European Institute of Health care was devoted to neuropsychopharmacology. As in previous meetings, we sought to choose topics that bridge the gap between basic neuroscience and the clinical fields of neurology and psychiatry. Consequently, the pro ceedings published in this supplement cover a lot of ground. Late breaking data on various neuromodulator and neurotransmitter systems and their implications for the treatment of a number of disorders are reviewed. Jean Charles Schwartz and colleagues set the stage with their paper on constitu tive receptor activity, using the histamine H3-receptor to illustrate the point. The role of neuropeptides and neurotrophins in psychiatric disorders is then reviewed by Florian Holsboer, while Bill Deakin elucidates the role of sero tonin, discovered 50 years ago in the brain, in select psychiatric syndromes. New pharmacological developments in the treatment of migraine, Parkin son's disease and schizophrenia are then presented by Hans Christoph Diener, Eduardo Tolosa and Wolfgang Fleischhacker. In the end David Nutt and colleagues provide future directions in substance dependence research, linking the role of various transmitter systems with findings from neu roimaging studies. In summary, there is no doubt that progress in the field of neuropsychopharmacology is exciting and the prospects of true advances in the treatment of brain disorders are very promising.

Paperback. Etat : new. Paperback. Substance-related disorders pose an increasing challenge not only to the field of psychiatry but also to public health. The rapid development of our society has also changed the face of substance use and abuse, both quantitatively and qualitatively. In this volume international experts present reviews of the latest research covering many areas ranging from neurobiology to psychological management, as well as different drugs, from alcohol to ecstasy. Substance-related disorders pose an increasing challenge not only to the field of psychiatry but also to public health. In this volume international experts present reviews of the latest research covering many areas ranging from neurobiology to psychological management, as well as different drugs, from alcohol to ecstasy. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Paperback. Etat : Brand New. 1st edition. 117 pages. 10.80x8.30x0.20 inches. In Stock.

Etat : As New. Unread book in perfect condition.

Etat : As New. Unread book in perfect condition.

Etat : As New. Unread book in perfect condition.

Etat : New.

Etat : New. pp. vii + 111 1st Edition.

Hardcover. Etat : Like New. Like New. book.

Etat : New. pp. vii + 111.

Paperback. Etat : new. Paperback. The 5th Neuropsychiatry Symposium of the European Institute of Health- care was devoted to neuropsychopharmacology. As in previous meetings, we sought to choose topics that bridge the gap between basic neuroscience and the clinical fields of neurology and psychiatry. Consequently, the pro- ceedings published in this supplement cover a lot of ground. Late breaking data on various neuromodulator and neurotransmitter systems and their implications for the treatment of a number of disorders are reviewed. Jean- Charles Schwartz and colleagues set the stage with their paper on constitu- tive receptor activity, using the histamine H3-receptor to illustrate the point. The role of neuropeptides and neurotrophins in psychiatric disorders is then reviewed by Florian Holsboer, while Bill Deakin elucidates the role of sero- tonin, discovered 50 years ago in the brain, in select psychiatric syndromes. New pharmacological developments in the treatment of migraine, Parkin- son's disease and schizophrenia are then presented by Hans Christoph Diener, Eduardo Tolosa and Wolfgang Fleischhacker.In the end David Nutt and colleagues provide future directions in substance dependence research, linking the role of various transmitter systems with findings from neu- roimaging studies. In summary, there is no doubt that progress in the field of neuropsychopharmacology is exciting and the prospects of true advances in the treatment of brain disorders are very promising. The 5th Neuropsychiatry Symposium of the European Institute of HealthA care was devoted to neuropsychopharmacology. As in previous meetings, we sought to choose topics that bridge the gap between basic neuroscience and the clinical fields of neurology and psychiatry. Consequently, the proA ceedings published in this supplement cover a lot of ground. Late breaking data on various neuromodulator and neurotransmitter systems and their implications for the treatment of a number of disorders are reviewed. JeanA Charles Schwartz and colleagues set the stage with their paper on constituA tive receptor activity, using the histamine H3-receptor to illustrate the point. The role of neuropeptides and neurotrophins in psychiatric disorders is then reviewed by Florian Holsboer, while Bill Deakin elucidates the role of seroA tonin, discovered 50 years ago in the brain, in select psychiatric syndromes. New pharmacological developments in the treatment of migraine, ParkinA son's disease and schizophrenia are then presented by Hans Christoph Diener, Eduardo Tolosa and Wolfgang Fleischhacker. In the end David Nutt and colleagues provide future directions in substance dependence research, linking the role of various transmitter systems with findings from neuA roimaging studies. In summary, there is no doubt that progress in the field of neuropsychopharmacology is exciting and the prospects of true advances in the treatment of brain disorders are very pro Shipping may be from our Sydney, NSW warehouse or from our UK or US warehouse, depending on stock availability.

Buch. Etat : Neu. Neuware -Substance-related disorders pose an increasing challenge not only to the field of psychiatry but also to public health. The rapid development of our society has also changed the face of substance use and abuse, both quantitatively and qualitatively. In this volume international experts present reviews of the latest research covering many areas ranging from neurobiology to psychological management, as well as different drugs, from alcohol to ecstasy.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 132 pp. Englisch.

Etat : New. pp. vii + 111.

Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Substance-related disorders pose an increasing challenge not only to the field of psychiatry but also to public health. The rapid development of our society has also changed the face of substance use and abuse, both quantitatively and qualitatively. In this volume international experts present reviews of the latest research covering many areas ranging from neurobiology to psychological management, as well as different drugs, from alcohol to ecstasy.

Buch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Substance-related disorders pose an increasing challenge not only to the field of psychiatry but also to public health. The rapid development of our society has also changed the face of substance use and abuse, both quantitatively and qualitatively. In this volume international experts present reviews of the latest research covering many areas ranging from neurobiology to psychological management, as well as different drugs, from alcohol to ecstasy.

Paperback. Etat : Brand New. 1st edition. 111 pages. 10.75x8.00x0.50 inches. In Stock.